COMP <GO>
ROIV vs UNH // FREE CASH FLOW YIELD
Roivant Sciences Ltd. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: ROIV 2
— UNH 12
▲ FREE CASH FLOW YIELD LEADER: UNH
LAST: $36.91 (-1.63%) • MKT CAP: $27.10B
fcf-yield
-2.80%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
fcf-yield
6.48%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ROIV VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ROIV | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 88.57% | -47.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -14.00% | 11.47% | -25.47 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -2.80% | 6.48% | -9.28 | UNH | /fcf-yield <GO> |
| Operating Margin | -60.00% | 4.82% | -64.82 | UNH | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 3.14% | -63.14 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 6.46% | -71.46 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 3.12 | +22.88 | ROIV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.74% | +0.16 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.3 | 56.0 | -1.76 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.33 | +0.67 | ROIV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | 17.1x | +10.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $27.10B | $364.66B | -$337.56B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ROIV REV | UNH REV | ROIV GROSS % | UNH GROSS % | ROIV FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.3M | $447.57B | 44.0% | 88.7% | -$758.6M | $16.07B |
| FY 2024 | $29.1M | $400.28B | 44.0% | 88.3% | -$844.0M | $20.70B |
| FY 2023 | $32.7M | $371.62B | 44.0% | 89.6% | -$766.7M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ROIV // BETA 1.00
UNH // BETA 0.33